Clinical and experimental studies pertinent for demonstrating the antipsychotic potential of benzodiazepines (BDZ) and the involvement of γ-aminobutyric acid (GABA) in the origin of schizophrenia are reviewed. It is shown that, due to severe methodological problems and pitfalls, placebo-controlled, double-blind studies do not permit unequivocal conclusions on the efficacy of BDZs, but neither do they completely disprove it. Furthermore, at first glance, confusing and controversial findings in animal models indicate a bi-directionality of effects of full BDZ agonists on dopamine-mediated functions, which may perhaps be explained by (i) anatomical and functional organization of the GABA-dopamine system in the nigro-striatal and ventro tegmental area, and (ii) the regional non-selectivity of action of these drugs. The recent demonstration of structural polymorphism of the GABAA-BDZ receptor complex and heterogeneous distribution of sets of subunits of the GABA A-BDZ receptor in the brain, suggests possibilities for development of partial BDZ agonists showing greater regional selectivity of action and thus potentially more specific antipsychotic action. Initial clinical results with bretazenil (Ro 16-6028), a partial BDZ agonist, in acute schizophrenia are, in this respect, an encouraging lead to be followed further.
Arana G.W., Ornsteen M.L., Kanter F. et al. (1986) The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Pharmacol Bull22: 77-87
2.
Azima H., Arthus D., Silver A. (1962) The effects of chlordiazepoxide (Librium) in anxiety states. Can Psychiatr Assoc J7: 44-50
3.
Bartholini G. (1980) Interaction of striatal dopaminergic, cholinergic and GABAergic neurons: relation to extrapyramidal function. Trends Pharmacol Sci1: 138-140
4.
Brockington I.F., Kendell R.E., Leff J.P. (1978) Definitions of schizophrenia: concordance and prediction of outcome. Psychol Med8: 387-398
5.
Carlsson M., Carlsson A. (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bull16: 425-432
6.
Cheramy A., Nievullan A., Glowinski J. (1979) GABAergic processes involved in the control of dopamine release from nigro-striatal dopaminergic neurons in the cat. Eur J Pharmacol48: 281-295
7.
Chouinard G., Annable L., Turnier L., Holobow N., Szkrumelak N. (1993) A double-blind randomized trial of rapid tranquilization with i.m. Clonazepam and i.m. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatr38 (suppl. 4): S114-8121
8.
Christensen A.V. (1981) Dopamine hyperactivity: effects of neuroleptics alone and in combination with GABA-agonists. In Perris C, Struwe G, Jansson B (eds), Biological psychiatry. Elsevier/North Holland, Press, pp. 823-832
9.
Christensen A.V., Arnt J., Scheel-Krüger J. (1979) Decreased antistereotypic effect of neuroleptics after additional treatment with a benzodiazepine, a GABA agonist or an anticholinergic compound. Life Sci24: 1395-1402
10.
Christensen A.V., Arnt J., Scheel-Krüger J. (1980) Gaba-dopamine/ neuroleptic interaction after systemic administration. Brain Res Bull5: 885-890
11.
Cross A.J., Owen F. ( 1980) Characteristics of 3H-cis-flupenthixol binding to calf brain membranes. Eur J Pharmacol65: 341-347
12.
Cross A.J., Crow T.J., Owen F. ( 1979) Gamma-aminobutyric acid in the brain in schizophrenia . Lanceti: 560-561
13.
Delini-Stula A. (1977) Baclofen-induced modification of conditioned discriminative avoidance behaviour and contraversive turning in the rat. Eur Pharmacol46: 265-274
14.
Delini-Stula A. (1979) Differential effects of baclofen and muscimol on behavioural responses implicating GABA-ergic transmission. In Kroosgard-Larsen P, Scheel-Krüger J, Kofod H (eds), GABAneurotransmitters, Alfred Benzon Symposium Vol 12. Munksgaard, pp. 482-497
15.
Delini-Stula A., Berdah-Tordjman D. (1994) Placebo-controlled studies in acute schizophrenia—an issue of concern. Eur Psychiatr9: 165-173
16.
Delini-Stula A., Berdah-Tordjman D., Neumann N. (1992) Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings. Clin Neuropharmacol15(suppl. 1): 405A-406A
17.
Domesick V.B. (1981) The anatomical basis for feedback and feedforward in the striatonigral system. In Gessa G L , Corsini G U (eds), Apomorphine and other dopaminomimetics, Vol. 1, Raven Press, New York, pp. 17-39
18.
Facklam M., Schoch P., Bonetti E.P., Janck F., Martin J.R., Moreau J.L., Haefely W. (1992) Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies . J Pharmacol Exp Ther261: 1113-1121
19.
Garza-Trevino E.S., Hollister L., Overall J.E. (1989) Efficacy of combination of intramuscular antipsychotics and sedative hypnotics for control of psychotic agitation. Am J Psychiatr146: 1598-1601
Grace A.A., Bunney B.S. (1985) Low doses of apomorphine elicit two opposing influences on dopamine cell electrophysiology. Brain Res333: 285-298
22.
Gundlach R., Engelhardt D.M., Hankoff L., Paley H., Rudorfer L., Bird E. ( 1966) A double-blind outpatient study of diazepam (valium) and placebo. Psychopharmacology9: 81-92
23.
Haefely W., Martin J.R., Schoch P. (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci11: 452-456
24.
Hankoff L.D., Rudorfer L., Paley H.M. (1962) A reference study of ataraxics: a two week double blind outpatient evaluation. J New Drugs2: 173-178
25.
Hekimian L.J., Friedhoff A.J. (1967) A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male schizophrenic patients. Dis Nerv Syst28: 675-678
26.
Holden J M C, Itil T.M., Keskiner A., Fink M. ( 1968) Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Compr Psychiatr9: 633-643
27.
Jimerson D.C., Van Kammen D.P., Post R.M., Docherty J.P., Bunney W.E. Jr (1982) Diazepam in schizophrenia: a preliminary doubleblind trial. Am J Psychiatr139: 489-491
28.
Keller H.H., Schaffner R., Haefely W. (1976) Interaction of benzodiazepines with neuroleptics of central dopamine neurons. Arch Pharmacol294: 1-7
29.
Kiuchi Y., Kobayashi T., Takeuchi J., Shimizu H., Ogata H., Toru M. ( 1989) Benzodiazepine receptors—increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychol Neurol Sci239: 71-78
30.
Lerner Y., Lwow E., Levitin A., Belmaker R.H. (1979) Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatr136: 1061-1064
31.
Lingjaerde O. (1983) Benzodiazepines in the treatment of schizophrenia . In Costa E (ed.), The benzodiazepines. From molecular biology to clinical practice. Raven Press, New York, pp. 369-381
32.
Lingjaerde O. (1985) Antipsychotic effect of the benzodiazepines. In Burrows G D, Norman T R, Davis B (eds), Drugs in psychiatry, antipsychotics, Vol. 3. Elsevier, Amsterdam, pp. 163-172
33.
Lingjaerde O. (1991) Benzodiazepines in the treatment of schizophrenia: an updated survey. Acta Psychiatr Scand84: 453-459
34.
Maculans G.A. (1964) Comparison of diazepam chlorprothixene and chlorpromazine in chronic schizophrenic patients. Dis Nerv Syst25: 164-168
35.
Martin J.R., Schoch P., Jenck F., Moreau J.L., Haefely W. (1993) Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from maximum to zero. Psychopharmacology111: 415-422
36.
Merlis S., Turner WJ, Krumholz W. (1962) A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients. J Neuropsychiatr3(suppl. 11): 133-138
37.
Merz W.A. (1991) Partial benzodiazepine agonists: new concepts in the treatment of panic disorder and schizophrenia. In Racagni G, Brunello N, Fukada T (eds), Biological psychiatry Vol. 1, Excerpta Medica, pp. 727-731
38.
Merz W.A., Alterwain P., Ballmer U., Bechelli L., Capponi R., Munoz J.G., Marquez C., Nestoros J., Almanzor L.R., Udabe R.U., Versiani M. (1988) Treatment of paranoid schizophrenia with the partial benzodiazepine agonist, Ro 16-6028. Psychopharmacology237: 95-96
39.
Nestoros J.N., Suranyi-Cadotte B.E., Spees R.C., Schwartz G., Nair N P V (1982) Diazepam in high doses is effective in schizophrenia . Prog Neuro-Psychopharmacol Biol Psychiatr6: 513-516
40.
Nestoros J.N., Nair N P V, Pulman J.R., Schwartz G., Bloom D. (1983) High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology81: 42-47
41.
Nishikawa T., Tsuda A., Tanaka M. (1982) Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology77: 301-304
42.
Pato C.N., Wolkowitz O.M., Rapaport M., Schulz S.C., Pickar D. (1989) Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull25: 263-266
43.
Perry T.L., Kish S.J., Buchanan J., Hansen S. (1979) γ-Aminobutyric-acid deficiency in brain of schizophrenic patients. Lanceti: 237-239
44.
Reynolds G.P., Czudek C., Andrews H.B. (1990) Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatr27: 1038-1044
45.
Richards G., Schoch P., Haefely W. (1991) Benzodiazepine receptors: new vistas. The Neurosciences3: 1991-1203
46.
Roberts E. (1972) An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosci Res Bull10: 468-481
47.
Scheel-Krüger J. (1986) Dopamine-GABA interactions: evidence that GABA transmits, modulates and mediates dopaminergic functions in the basal ganglia and the limbic system. Acta Neurol Scand73(Suppl 107): 1-54
48.
Scheel-Krüger J., Arnt J., Braestrup C., Christensen A.V., Magelund G. (1979) Development of new animal models for Gaba-ergic actions using muscimol as a tool. In Krogsgaard-Larsen P, Scheel-Krüger J, Kofod H (eds), GABA neurotransmitters. Pharmacochemical, biochemical and pharmacological aspects. Academic Press , Copenhagen/New York, pp. 447-464
49.
Scheel-Krüger J., Arnt J., Magelund G., Olianas M., Przwlocka B., Christensen A.V. (1980) Behavioural functions of GABA in basal ganglia and limbic system. Brain Res Bull5: 261-267
50.
Sigel E., Baur R., Trube G., Möhler H., Malherbe P. (1990) The effect of subunit composition of rat brain GABA-A receptors on channel function. Neuron5: 703-711
51.
Simpson M D C, Slater P., Deakin J F W, Royston M.C., Skan W.J. (1989) Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett107: 211-215
52.
Smith ME (1961) A clinical study of chlorpromazine and chlordiazepoxide . Conn Med25: 153-157
53.
Spokes E G S, Garrett N.J., Rossor M.N., Iversen L.L. (1980) Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J Neurol Sci48: 303-313
54.
Squires R.F., Saederup E. (1991) A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis . Neurochem Res16: 1099-1111
55.
Squires R.F., Lajtha A., Saederup E., Palkovits M. (1993) Reduced [3H] flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res18: 219-223
56.
Stephen J.H., Astrup C., Carpenter W., Schaffer J.W., Goldberg J.A. (1982) Comparison of 9 systems to diagnose schizophrenia . Psychiatr Res6: 127-143
57.
Stevens J., Wilson K., Foote W. (1974) GABA blockade, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacology39: 105-119
58.
Stonehill E., Lee H., Ban T.A. (1966) A comparative study with benzodiazepines in chronic psychotic patients. Dis Nerv Syst27: 411-413
59.
Toru M. et al. (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand78: 121-137
60.
Venkoba Rao S. (1964) A controlled trial with "Valium" in some psychiatric disorders. Indian J Psychiatr4: 188-192
61.
Wallace K.H., Thompson R.A. (1991) Immunointervention in man: a critique of clinical trial methodology. Oxford University Press, Oxford.
62.
Waszczak B.L., Bergstrom D.A., Walters J.R. (1981) Single unit responses of substantia nigra and globus pallidus neurons to GABA agonists and antagonists drug. In Di Chiara G, Gessa G L (eds), GABA and the basal ganglia. Advances in biochemical psychopharmacology . Vol. 30. Raven Press, New York, pp. 79-94
63.
Wolkowitz O.M., Pickar D. (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatr148: 714-726
64.
Wood P.L. (1982) Actions of GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther222: 674-679
